Cargando…

A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas

BACKGROUND: Targeted therapy for non-small cell lung cancer is histology dependent. However, histological classification by routine pathological assessment with hematoxylin-eosin staining and immunostaining for poorly differentiated tumors, particularly those from small biopsies, is still challengin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin, Shi, Gengen, Chu, Qingsong, Jiang, Wenbin, Liu, Yixin, Zhang, Sainan, Zhang, Zheyang, Wei, Zixin, He, Fei, Guo, Zheng, Qi, Lishuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868745/
https://www.ncbi.nlm.nih.gov/pubmed/31752667
http://dx.doi.org/10.1186/s12864-019-6086-2
_version_ 1783472334367096832
author Li, Xin
Shi, Gengen
Chu, Qingsong
Jiang, Wenbin
Liu, Yixin
Zhang, Sainan
Zhang, Zheyang
Wei, Zixin
He, Fei
Guo, Zheng
Qi, Lishuang
author_facet Li, Xin
Shi, Gengen
Chu, Qingsong
Jiang, Wenbin
Liu, Yixin
Zhang, Sainan
Zhang, Zheyang
Wei, Zixin
He, Fei
Guo, Zheng
Qi, Lishuang
author_sort Li, Xin
collection PubMed
description BACKGROUND: Targeted therapy for non-small cell lung cancer is histology dependent. However, histological classification by routine pathological assessment with hematoxylin-eosin staining and immunostaining for poorly differentiated tumors, particularly those from small biopsies, is still challenging. Additionally, the effectiveness of immunomarkers is limited by technical inconsistencies of immunostaining and lack of standardization for staining interpretation. RESULTS: Using gene expression profiles of pathologically-determined lung adenocarcinomas and squamous cell carcinomas, denoted as pADC and pSCC respectively, we developed a qualitative transcriptional signature, based on the within-sample relative gene expression orderings (REOs) of gene pairs, to distinguish ADC from SCC. The signature consists of two genes, KRT5 and AGR2, which has the stable REO pattern of KRT5 > AGR2 in pSCC and KRT5 < AGR2 in pADC. In the two test datasets with relative unambiguous NSCLC types, the apparent accuracy of the signature were 94.44 and 98.41%, respectively. In the other integrated dataset for frozen tissues, the signature reclassified 4.22% of the 805 pADC patients as SCC and 12% of the 125 pSCC patients as ADC. Similar results were observed in the clinical challenging cases, including FFPE specimens, mixed tumors, small biopsy specimens and poorly differentiated specimens. The survival analyses showed that the pADC patients reclassified as SCC had significantly shorter overall survival than the signature-confirmed pADC patients (log-rank p = 0.0123, HR = 1.89), consisting with the knowledge that SCC patients suffer poor prognoses than ADC patients. The proliferative activity, subtype-specific marker genes and consensus clustering analyses also supported the correctness of our signature. CONCLUSIONS: The non-subjective qualitative REOs signature could effectively distinguish ADC from SCC, which would be an auxiliary test for the pathological assessment of the ambiguous cases.
format Online
Article
Text
id pubmed-6868745
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68687452019-12-12 A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas Li, Xin Shi, Gengen Chu, Qingsong Jiang, Wenbin Liu, Yixin Zhang, Sainan Zhang, Zheyang Wei, Zixin He, Fei Guo, Zheng Qi, Lishuang BMC Genomics Research Article BACKGROUND: Targeted therapy for non-small cell lung cancer is histology dependent. However, histological classification by routine pathological assessment with hematoxylin-eosin staining and immunostaining for poorly differentiated tumors, particularly those from small biopsies, is still challenging. Additionally, the effectiveness of immunomarkers is limited by technical inconsistencies of immunostaining and lack of standardization for staining interpretation. RESULTS: Using gene expression profiles of pathologically-determined lung adenocarcinomas and squamous cell carcinomas, denoted as pADC and pSCC respectively, we developed a qualitative transcriptional signature, based on the within-sample relative gene expression orderings (REOs) of gene pairs, to distinguish ADC from SCC. The signature consists of two genes, KRT5 and AGR2, which has the stable REO pattern of KRT5 > AGR2 in pSCC and KRT5 < AGR2 in pADC. In the two test datasets with relative unambiguous NSCLC types, the apparent accuracy of the signature were 94.44 and 98.41%, respectively. In the other integrated dataset for frozen tissues, the signature reclassified 4.22% of the 805 pADC patients as SCC and 12% of the 125 pSCC patients as ADC. Similar results were observed in the clinical challenging cases, including FFPE specimens, mixed tumors, small biopsy specimens and poorly differentiated specimens. The survival analyses showed that the pADC patients reclassified as SCC had significantly shorter overall survival than the signature-confirmed pADC patients (log-rank p = 0.0123, HR = 1.89), consisting with the knowledge that SCC patients suffer poor prognoses than ADC patients. The proliferative activity, subtype-specific marker genes and consensus clustering analyses also supported the correctness of our signature. CONCLUSIONS: The non-subjective qualitative REOs signature could effectively distinguish ADC from SCC, which would be an auxiliary test for the pathological assessment of the ambiguous cases. BioMed Central 2019-11-21 /pmc/articles/PMC6868745/ /pubmed/31752667 http://dx.doi.org/10.1186/s12864-019-6086-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Li, Xin
Shi, Gengen
Chu, Qingsong
Jiang, Wenbin
Liu, Yixin
Zhang, Sainan
Zhang, Zheyang
Wei, Zixin
He, Fei
Guo, Zheng
Qi, Lishuang
A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas
title A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas
title_full A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas
title_fullStr A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas
title_full_unstemmed A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas
title_short A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas
title_sort qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868745/
https://www.ncbi.nlm.nih.gov/pubmed/31752667
http://dx.doi.org/10.1186/s12864-019-6086-2
work_keys_str_mv AT lixin aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT shigengen aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT chuqingsong aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT jiangwenbin aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT liuyixin aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT zhangsainan aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT zhangzheyang aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT weizixin aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT hefei aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT guozheng aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT qilishuang aqualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT lixin qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT shigengen qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT chuqingsong qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT jiangwenbin qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT liuyixin qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT zhangsainan qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT zhangzheyang qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT weizixin qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT hefei qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT guozheng qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas
AT qilishuang qualitativetranscriptionalsignatureforthehistologicalreclassificationoflungsquamouscellcarcinomasandadenocarcinomas